OC514 / Oncocross - LARVOL DELTA

Oncocross Completes Phase I Global Clinical Trial of OC514, Treatment for Sarcopenia (Businesswire) - "Oncocross...announced the completion of phase 1 global clinical trial of OC514, a treatment targeting sarcopenia and other rare muscular diseases. Phase 1 was conducted in Australia...The study was conducted as a randomized, double-blind, dose-ranging, placebo-controlled to evaluate the safety, pharmacokinetics, and pharmacodynamic effects of OC514 in 28 healthy volunteers."

Trial status • Cachexia • Genetic Disorders • Sarcopenia

A First in Human Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics Effects of OC514 (clinicaltrials.gov) - P1 | N=23 | Completed | Sponsor: Oncocross Australia Pty Ltd. | Not yet recruiting ➔ Completed | Trial completion date: Jun 2022 ➔ Mar 2023 | Trial primary completion date: May 2022 ➔ Sep 2022

Trial completion • Trial completion date • Trial primary completion date • Cachexia • Oncology